Berberine for Blood Sugar & Glycemic Control

Table of Contents

1. The Yin 2008 Trial — Berberine vs Metformin Head-to-Head
2. Lan 2015 & Dong 2012 Meta-Analyses
3. AMP-Activated Protein Kinase — The Shared Mechanism With Metformin
4. Beyond AMP-Activated Protein Kinase — GLUT4, Dipeptidyl Peptidase-4, and Microbiome
5. "Nature's Metformin" — What the Nickname Gets Right and Wrong
6. Doses Used in Trials — 500 mg Three Times Daily With Meals
7. Gastrointestinal Side Effects and What Reduces Them
8. Situations Where Berberine Is Discussed
9. Berberine for Prediabetes and Impaired Glucose Tolerance
10. Drug Interactions and Contraindications
11. Monitoring — Hemoglobin A1c, Fasting Glucose, and Fasting Insulin
12. Key Research Papers
13. Connections
14. Featured Videos

The Yin 2008 Trial — Berberine vs Metformin Head-to-Head

The 2008 Yin trial published in Metabolism is the single most-cited piece of clinical evidence for berberine in type 2 diabetes. In this pilot study, investigators at the Department of Endocrinology of Xinhua Hospital (Shanghai Jiaotong University School of Medicine), working with the Pennington Biomedical Research Center in the United States, enrolled 36 newly diagnosed patients with type 2 diabetes mellitus and randomized them to either:

• Berberine 500 mg three times daily before meals (1,500 mg/day total)
• Metformin 500 mg three times daily before meals (1,500 mg/day total)

After three months of treatment, the authors report that the blood-sugar-lowering effect of berberine was similar to that of metformin. The published abstract gives these figures for the berberine group:

• Hemoglobin A1c reduction — hemoglobin A1c fell from 9.5% to 7.5% (p<0.01).
• Fasting plasma glucose — fell from 10.6 to 6.9 mmol/L (p<0.01).
• Postprandial (after-meal) plasma glucose — fell from 19.8 to 11.1 mmol/L (p<0.01).
• Triglycerides — fell from 1.13 to 0.89 mmol/L (p<0.05), a finding consistent with berberine's additional lipid mechanism (see the cholesterol deep-dive).
• Side effects — across this trial and a second 48-patient study reported in the same paper, 20 patients (34.5%) had transient gastrointestinal side effects; no liver or kidney damage was found in any patient.

The trial is small (n=36), its authors call it a pilot study, and it was conducted at a single Chinese center, so on its own it is limited evidence. But it established the proof-of-concept that berberine lowers blood sugar in a range comparable to metformin, and it provided the dosing template (500 mg three times daily with meals) that most subsequent berberine diabetes trials have followed.

A common patient question is "if berberine equals metformin, why isn't it the first-line drug?" The honest answer is that the trial base for metformin is enormously larger (the UK Prospective Diabetes Study alone enrolled over 5,000 patients with 20-year follow-up), metformin is U.S. Food and Drug Administration-approved with a known safety profile across millions of patient-years, metformin is inexpensive ($4/month at most U.S. pharmacies), and metformin's daily pill burden is lower (the extended-release label gives one dose a day with the evening meal, up to 2,000 mg, vs three times daily for berberine). Berberine is usually discussed not as a replacement for metformin but as an alternative for people who cannot take metformin and as a possible add-on for people who need more glucose lowering on top of metformin.

Back to Table of Contents

Lan 2015 & Dong 2012 Meta-Analyses

Two large meta-analyses have now pooled the berberine-for-diabetes trial evidence and found a glucose-lowering effect. The Dong et al. 2012 systematic review in Evidence-Based Complementary and Alternative Medicine pooled 14 trials with 1,068 participants, lasting 8 to 24 weeks, and reported:

• Hemoglobin A1c reduction: mean difference -0.72% (95% confidence interval (CI) -0.97 to -0.47, p<0.00001) for berberine plus lifestyle change compared with lifestyle change alone or with placebo
• Fasting plasma glucose reduction: mean difference -0.87 mmol/L (95% CI -1.20 to -0.54) in the same comparison
• Postprandial plasma glucose reduction: mean difference -1.72 mmol/L (95% CI -2.32 to -1.11) in the same comparison
• Berberine alone did not give significantly better glucose control than metformin, glipizide or rosiglitazone alone in head-to-head trials
• Berberine added to oral diabetes drugs lowered hemoglobin A1c by a further 0.53% (95% CI -0.95 to -0.11) compared with the same drugs alone, suggesting additive (non-overlapping) mechanisms in vivo
• The authors rated the methodological quality of the trials as “generally low” and wrote that the evidence “should be carefully interpreted due to the low methodological quality, small sample size, limited number of trials, and unidentified risks of bias”

The Lan et al. 2015 meta-analysis in Journal of Ethnopharmacology pooled 27 trials (2,569 participants) and reached very similar conclusions:

• Hemoglobin A1c reduction: weighted mean difference approximately -0.7 to -0.9% across analyses
• Fasting glucose reduction: weighted mean difference approximately -0.8 to -1.0 mmol/L
• In head-to-head comparisons there was no statistically significant difference between berberine and oral diabetes drugs (the review did not run a formal non-inferiority test)
• Safety: “no serious adverse reaction was reported in the 27 experiments”
• The authors concluded that, because of the limited quality of the included studies, “the therapeutic benefit of berberine can be substantiated to a limited degree”, and called for larger, better-designed trials using standardized preparations

The convergence of two independent meta-analyses on approximately the same effect size — hemoglobin A1c reduction of 0.7 to 0.9% — is reassuring. For reference, this is in the same range as most oral diabetes drugs (metformin 1.0-1.5%, sulfonylureas 1.0-2.0%, dipeptidyl peptidase-4 inhibitors 0.5-0.8%, sodium-glucose cotransporter-2 (SGLT2) inhibitors 0.5-1.0%). The qualifier on the meta-analytic evidence is that most underlying trials are Chinese and small, and both reviews rate their quality as low; large Western multi-center trials are still lacking.

A 2023 review from the University of Hong Kong took a stricter approach and pooled only placebo-controlled trials (20 trials, 1,761 people). Compared with placebo, berberine lowered fasting glucose by 0.52 mmol/L (95% CI -0.72 to -0.33), hemoglobin A1c by 4.48 mmol/mol (95% CI -6.53 to -2.44; 7 trials) and 2-hour post-meal glucose by 1.81 mmol/L (4 trials). The fall in fasting glucose looked larger in women, in people with diabetes and in Asian participants, but the authors note these subgroup results still need to be repeated because few studies were available.

But the consistency of the signal across trials, mechanisms, and outcome measures makes the glycemic effect one of the best-supported claims in herbal pharmacology.

Back to Table of Contents

AMP-Activated Protein Kinase — The Shared Mechanism With Metformin

AMP-activated protein kinase (AMPK) is a heterotrimeric enzyme complex that functions as the cellular fuel sensor. When cellular energy is low (the AMP:ATP ratio rises), AMP-activated protein kinase is phosphorylated and activated. Once active, AMP-activated protein kinase orchestrates a coordinated response to restore energy:

• Increases glucose uptake into cells (via GLUT4 translocation in muscle, GLUT1 elsewhere)
• Increases fatty acid oxidation (via inhibition of acetyl-CoA carboxylase)
• Inhibits fatty acid synthesis and cholesterol synthesis (energy-expensive anabolic pathways)
• Stimulates mitochondrial biogenesis (via the regulator protein peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PGC-1α)
• Inhibits hepatic gluconeogenesis (the liver's production of new glucose)
• Triggers autophagy (recycling of damaged cellular components for energy)

The net metabolic phenotype of AMP-activated protein kinase activation is exactly what a type 2 diabetic patient needs: more glucose uptake into cells, less hepatic glucose output, more fat burning, less fat storage. This is precisely why AMP-activated protein kinase is the principal molecular target of metformin — the most prescribed diabetes drug in the world.

Berberine activates AMP-activated protein kinase through a different upstream mechanism than metformin (metformin inhibits mitochondrial complex I to raise cellular AMP; berberine appears to act both through a similar mitochondrial inhibition and through direct activation of LKB1, the upstream kinase that phosphorylates AMP-activated protein kinase). The downstream consequences, however, are nearly identical, which is why the clinical phenotype — reduced hemoglobin A1c, reduced fasting glucose, improved insulin sensitivity — is also nearly identical.

The clinical implication is that berberine and metformin are not expected to be additive on the AMP-activated protein kinase pathway alone. The Dong meta-analysis finding of larger hemoglobin A1c reductions with the combination is therefore informative — it suggests that berberine's non-AMPK mechanisms (dipeptidyl peptidase-4, GLUT4-direct, microbiome) provide the additive benefit. See the AMP-activated protein kinase and Metabolic Syndrome page for the broader systemic implications of AMP-activated protein kinase activation beyond glucose.

Back to Table of Contents

Beyond AMP-Activated Protein Kinase — GLUT4, Dipeptidyl Peptidase-4, and Microbiome

Berberine's glycemic effect is not purely AMP-activated protein kinase-mediated. Three additional mechanisms have been characterized:

GLUT4 translocation — independent of AMP-activated protein kinase, berberine appears to directly stimulate translocation of the insulin-responsive glucose transporter GLUT4 from intracellular vesicles to the plasma membrane of skeletal muscle and adipocyte cells. This is the same translocation event that insulin triggers, and it explains why berberine improves insulin sensitivity even in patients with relatively low fasting insulin. The mechanism resembles the effect of exercise on GLUT4 (which is also AMP-activated protein kinase-independent in part) and is why some authors describe berberine as an "exercise mimetic" in addition to a metformin mimetic.

Modest dipeptidyl peptidase-4 inhibition — berberine has measurable inhibitory activity against dipeptidyl peptidase-4, the enzyme that rapidly degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) after they are secreted by intestinal L-cells and K-cells in response to meals. Prescription dipeptidyl peptidase-4 inhibitors (sitagliptin, linagliptin, saxagliptin) are a well-established diabetes drug class because raising effective glucagon-like peptide-1 levels improves post-prandial glucose control. Berberine's dipeptidyl peptidase-4 inhibition is modest compared to these prescription agents but contributes additively to its glucose-lowering effect, particularly post-prandial.

Microbiome modulation — this is one of the most exciting recent findings. Berberine, because of its poor systemic bioavailability, exists at high concentrations in the gut lumen, where it directly modifies the gut microbiome. Studies in both rodent models and human patients have shown that berberine shifts the microbial composition toward a phenotype associated with improved glucose metabolism — increased Akkermansia muciniphila, increased short-chain fatty acid producers, decreased lipopolysaccharide-producing Gram-negatives. The reduced metabolic endotoxemia (lower circulating lipopolysaccharide (LPS), lower toll-like receptor 4 (TLR4) signaling) is now thought to account for a meaningful fraction of berberine's glycemic and insulin-sensitivity effects, independent of any direct molecular activity on host enzymes.

The multi-mechanism nature of berberine's glycemic effect is the modern pharmacology explanation for why a single botanical compound can produce effects comparable to several entirely separate drug classes (metformin, gliptins, gliflozins via the microbiome).

Back to Table of Contents

"Nature's Metformin" — What the Nickname Gets Right and Wrong

The popular framing of berberine as "nature's metformin" is both informative and misleading. It is informative in the sense that:

• Both compounds activate AMP-activated protein kinase as their principal molecular target
• Both reduce hemoglobin A1c by approximately the same amount (0.7-0.9%) in head-to-head trials
• Both reduce hepatic gluconeogenesis
• Both improve insulin sensitivity without causing hypoglycemia in monotherapy
• Both have transient gastrointestinal side effects (diarrhea, cramping, nausea) that resolve with continued use

It is misleading in the sense that:

• Berberine is not a botanical version of metformin chemically — they have entirely different structures (metformin is a synthetic biguanide; berberine is a natural isoquinoline alkaloid). The shared phenotype reflects convergent pharmacology, not chemical resemblance.
• Berberine has additional mechanisms (lipid-lowering via low-density lipoprotein receptor (LDLR) upregulation, antimicrobial activity, gut-microbiome modulation) that metformin lacks. Some of these are useful, some are simply additional considerations.
• Berberine has a much smaller evidence base for cardiovascular outcomes, all-cause mortality, and cancer prevention than metformin does — metformin has 40+ years of post-marketing data; berberine has perhaps 15 years.
• Berberine costs approximately $20-30/month for a quality product, vs $4-10/month for generic metformin.
• Metformin is U.S. Food and Drug Administration-approved as a drug, with manufacturing oversight; berberine is sold as a dietary supplement, and only some products go through independent third-party testing.

The fair framing: berberine is discussed as an alternative to metformin in people who cannot tolerate metformin (lactic acidosis risk, B12 depletion concern, severe gastrointestinal intolerance, contrast-imaging interruptions) or who actively prefer a botanical approach, and as an add-on for people on metformin who need more glucose lowering.

Back to Table of Contents

Doses Used in Trials — 500 mg Three Times Daily With Meals

The standard berberine dose for glycemic control is 500 mg three times daily with meals (1,500 mg/day total). This is the dose used in the Yin 2008 trial and in the majority of subsequent diabetes trials. Practical considerations:

• With meals, not on an empty stomach. Practitioners report that food greatly reduces the gastrointestinal side effects (cramping, urgent diarrhea) that occur when berberine is taken fasting.
• Three divided doses are used because berberine has a relatively short half-life (approximately 4-5 hours for the parent compound). A single 1,500 mg dose would produce peak-trough fluctuations that reduce efficacy and increase per-dose side effects. Twice-daily dosing (750 mg twice daily) is used by some people who cannot manage three doses, and some report it is enough.
• Gradual start. A common practitioner schedule begins with 500 mg once daily with the largest meal for 4-7 days, then 500 mg twice daily for another 4-7 days, then the full 500 mg three times daily. Practitioners report that this gradual increase largely prevents the early gastrointestinal side effects that lead many people to stop.
• Product labels. Berberine hydrochloride ("berberine HCl") is the most-studied salt form, usually sold at 500 mg per capsule. Products labelled "berberine complexes" or "berberine blends" can contain less berberine than the name implies. Independent third-party testing programs for supplements exist and check that the contents match the label.
• Cycling. Some online sources suggest cycling berberine on/off in 3-month intervals to avoid "tolerance." No trial has tested whether tolerance develops; the trials pooled in the 2012 Dong review lasted 8 to 24 weeks, so what happens over years of daily use is not known.

For higher-bioavailability alternatives (dihydroberberine, berberine + sodium caprate), the per-dose amount is lower (typically 100-200 mg dihydroberberine equivalent) but the dosing frequency (three times daily with meals) is the same. There is no convincing trial evidence that these enhanced forms are clinically superior to standard berberine HCl at the standard dose — they may simply allow smaller pills and fewer gastrointestinal side effects.

Back to Table of Contents

Gastrointestinal Side Effects and What Reduces Them

The most common and predictable berberine side effect is gastrointestinal — loose stools, cramping, urgency, and occasionally nausea. In the published trials, approximately 30-40% of patients report some gastrointestinal symptom in the first two weeks, dropping to under 10% after the first month as the gut adapts. The mechanism appears to be a combination of direct osmotic effect on the gut, mild antimicrobial activity altering the microbiome, and stimulation of bile acid secretion.

The measures practitioners and users describe, roughly in order of importance:

1. Taking it with food. Described as the single most important measure: people report that berberine taken fasting is reliably uncomfortable, while berberine taken at the start of a substantial meal is usually tolerated.
2. A gradual increase over 2-3 weeks as described above. Practitioners describe starting at the full 1,500 mg/day as the most common reason people stop.
3. Fluid intake. Practitioners report that dehydrated people tolerate berberine poorly, which fits the osmotic part of the effect.
4. Smaller divided doses — for example 250 mg with each meal plus 250 mg with a substantial snack, instead of 500 mg three times daily.
5. Dihydroberberine — people who do not tolerate standard berberine report that its smaller per-dose amount (100-200 mg) often eases remaining gastrointestinal symptoms.
6. Probiotics in the first month. Berberine's antimicrobial activity is mostly desirable (see the small intestinal bacterial overgrowth (SIBO) and gut health deep-dive) but can disrupt commensals transiently; practitioners report that a multi-strain probiotic taken at a different time of day than berberine helps with stool consistency.

When gastrointestinal symptoms last beyond a month despite these measures, berberine is probably a poor fit for that person. The other options people turn to are dihydroberberine, other botanicals traditionally used for blood sugar (gymnema, bitter melon, cinnamon), or prescription medicines.

Back to Table of Contents

Situations Where Berberine Is Discussed

The situations in which berberine is most often discussed for blood sugar are:

• Metformin-intolerant type 2 diabetics — patients who cannot tolerate metformin due to severe gastrointestinal symptoms (even after extended-release and gradual titration), B12-depletion concerns, or reduced kidney function. The metformin label rules it out when the estimated glomerular filtration rate (eGFR) is below 30 mL/min/1.73 m², does not recommend starting it at an eGFR of 30-45, and calls for a risk-benefit review if eGFR falls below 45 during treatment. Berberine has a different side-effect profile, but none of the berberine trials cited here studied people with chronic kidney disease (CKD).
• Pre-diabetes / impaired glucose tolerance — people with hemoglobin A1c 5.7-6.4% who want more than lifestyle change alone but who do not yet meet the threshold for prescription diabetes therapy. Berberine's tolerability is the main reason it is discussed here; the trial evidence in prediabetes itself is small — see the prediabetes section below.
• Adjunct to metformin in inadequately controlled diabetes — the Dong meta-analysis found that berberine added to oral diabetes drugs lowered hemoglobin A1c by a further 0.53% compared with the same drugs alone. Practitioners discuss it for people on metformin alone whose hemoglobin A1c stays at 7.5-8.5% (above goal but not so high as to require insulin), before a second prescription drug.
• Polycystic ovary syndrome (PCOS) with insulin resistance — the Wei 2012 trial in European Journal of Endocrinology gave 89 Chinese women with polycystic ovary syndrome and insulin resistance berberine, metformin or placebo for 3 months, each alongside the hormone drug cyproterone acetate. Compared with metformin, berberine lowered waist circumference, waist-to-hip ratio, total cholesterol, triglycerides and LDL cholesterol and raised HDL cholesterol and sex hormone-binding globulin; compared with placebo it also lowered fasting glucose, fasting insulin and insulin resistance (HOMA-IR). The authors concluded it “improved some of the metabolic and hormonal derangements”; the trial did not report ovulation or pregnancy outcomes. See the AMP-activated protein kinase and Metabolic Syndrome page for the polycystic ovary syndrome evidence in detail.
• Patients with concurrent dyslipidemia — berberine's additional low-density lipoprotein-receptor mechanism produces meaningful lipid-lowering on top of the glycemic effect. A diabetic patient with hemoglobin A1c 7.5% and low-density lipoprotein (LDL) 140 mg/dL gets a "two-for-one" benefit that pure metformin does not provide. See the cholesterol deep-dive.
• Patients with small intestinal bacterial overgrowth or significant gut dysbiosis — the berberine antimicrobial activity is a clinically useful side effect rather than a bug. See the gut health deep-dive.

Berberine has no role in type 1 diabetes (insulin deficiency, not insulin resistance), its effect size is too small for advanced type 2 diabetes requiring insulin (severe insulin deficiency), and it is listed as contraindicated in pregnancy and breastfeeding (see the drug interactions section).

Back to Table of Contents

Berberine for Prediabetes and Impaired Glucose Tolerance

Prediabetes (hemoglobin A1c 5.7-6.4%, or fasting glucose 100-125 mg/dL, or a 2-hour oral glucose tolerance test (OGTT) of 140-199 mg/dL) is the use most often discussed for berberine in people without diabetes. The clinical reasoning is straightforward: prediabetes increases the risk of progression to overt diabetes by approximately 10% per year, but most prediabetic patients cannot or will not take prescription metformin (off-label, hard to get insurance coverage for, requires a clinician comfortable with off-label prescribing). Lifestyle intervention (Mediterranean diet, 150 minutes/week of activity, weight loss of 5-7%) is the evidence-based first-line, but only a fraction of patients achieve and sustain the necessary lifestyle change.

The trial evidence for berberine in prediabetes is small. A 2023 randomized, double-blind, placebo-controlled pilot trial in India gave 34 people with prediabetes berberine 500 mg three times daily or a placebo for 12 weeks. In the berberine group:

• Hemoglobin A1c fell from 6.40% to 5.43%
• Fasting plasma glucose fell from 6.75 to 5.33 mmol/L, and the 2-hour oral glucose tolerance test from 10.44 to 8.12 mmol/L
• Homeostatic model assessment of insulin resistance (HOMA-IR) (a measure of insulin resistance) fell from 3.61 to 2.41; the differences from the placebo group were statistically significant
• No severe side effects and no kidney or liver toxicity were found

The trial was small, short and tested a single commercial berberine product.

The schedule practitioners describe for prediabetes:

1. Prediabetes is confirmed with two hemoglobin A1c values of 5.7-6.4% or two fasting glucose values of 100-125 mg/dL
2. Mediterranean or low-carb dietary changes go alongside it — practitioners treat berberine as an adjunct to lifestyle, not a substitute
3. Berberine starts at 500 mg once daily with the largest meal and rises to 500 mg three times daily over 2-3 weeks
4. Hemoglobin A1c is rechecked at 3 months; practitioners look for a fall of 0.3-0.7%
5. When it works and is tolerated, practitioners continue it long term; with no effect after 6 months at full dose, they stop it
6. Follow-up is at least yearly with hemoglobin A1c, fasting glucose, fasting insulin, and a lipid panel

For more on prediabetes and insulin resistance management, see the Insulin Resistance page and the Hemoglobin A1C lab test page.

Back to Table of Contents

Drug Interactions and Contraindications

Berberine is a meaningful inhibitor of cytochrome P450 enzymes (CYP2D6, CYP3A4, CYP2C9) and the P-glycoprotein efflux transporter. This produces clinically significant drug interactions:

• Cyclosporine — berberine increases cyclosporine blood levels significantly, a concern for transplant patients who take cyclosporine for immunosuppression.
• Macrolide antibiotics (clarithromycin, erythromycin) — potential for additive cytochrome P450 3A4 (CYP3A4) interaction and QT prolongation (a heart-rhythm change).
• Warfarin — berberine may increase warfarin effect through CYP2C9 inhibition, which shows up as a rising international normalized ratio (INR), the blood test that tracks warfarin.
• Diabetes medications (insulin, sulfonylureas, meglitinides) — additive hypoglycemic effect possible: in people combining berberine with insulin or sulfonylureas, blood sugar can fall lower than expected, and the prescription doses are sometimes lowered.
• Selective serotonin reuptake inhibitors (SSRIs) and other cytochrome P450 2D6 (CYP2D6) substrates — berberine may increase serum levels of fluoxetine, paroxetine, venlafaxine, atomoxetine, and other cytochrome P450 2D6-metabolized drugs.
• Statins — pharmacokinetic interactions are modest and the pharmacodynamic combination is actually clinically useful (see the cholesterol deep-dive). The combination is used in practice.

The situations generally listed as contraindications are:

• Pregnancy — berberine displaces bilirubin from albumin and crosses the placenta, with concern for fetal kernicterus (bilirubin damage to the brain), particularly in late pregnancy. A 1993 laboratory study found berberine pushed bilirubin off albumin about ten times more strongly than phenylbutazone, a known bilirubin displacer, and raised unbound bilirubin in rats; its author concluded that herbs rich in berberine are “best avoided in jaundiced neonates and pregnant women.”
• Lactation — berberine appears in breast milk in measurable quantities. The newborn liver cannot conjugate berberine adequately, so the bilirubin-displacement concern carries over to breastfeeding.
• Neonates and infants — in 1978 in Singapore, Rhizoma coptidis (huanglian, a herb rich in berberine) was implicated in newborn jaundice and kernicterus in babies with glucose-6-phosphate dehydrogenase (G6PD) deficiency, an inherited enzyme shortage. Singapore then banned the herb and berberine. More than three decades later, with growing safety evidence for the general public and a better understanding of G6PD deficiency, Singapore's Health Sciences Authority reviewed and lifted the ban. The laboratory basis for the newborn concern is the bilirubin displacement described above.

The relative contraindications include severe hepatic impairment (berberine is hepatically metabolized; clearance is reduced), and any patient on multiple CYP-metabolized medications where the cumulative interaction burden makes herbal additions risky. For people on many prescription medicines, the relevant fact is that berberine inhibits CYP2D6, CYP3A4, CYP2C9 and P-glycoprotein, so every added medicine cleared by those pathways adds to the interaction risk.

Back to Table of Contents

Monitoring — Hemoglobin A1c, Fasting Glucose, and Fasting Insulin

The monitoring schedule practitioners describe for a person taking berberine for blood sugar is:

• Baseline — hemoglobin A1c, fasting plasma glucose, fasting insulin (for homeostatic model assessment of insulin resistance calculation), lipid panel (total, low-density lipoprotein, high-density lipoprotein (HDL), triglycerides), liver function (aspartate aminotransferase (AST), alanine aminotransferase (ALT)), basic metabolic panel (creatinine, estimated glomerular filtration rate (eGFR)).
• 3 months — recheck hemoglobin A1c, fasting glucose, fasting insulin. The hemoglobin A1c reduction is expected to be measurable by this point if berberine is working (typically 0.3-0.9% reduction depending on baseline).
• 6 months — recheck hemoglobin A1c and full lipid panel. The lipid effect (low-density lipoprotein reduction of 20-29%) is typically maximal by 3-6 months.
• Annually thereafter — hemoglobin A1c, fasting glucose, fasting insulin, lipid panel, liver function. The trials pooled in the 2012 Dong review lasted 8 to 24 weeks, so safety data over years of continuous use are limited.

The relevant lab pages on this site:

• Hemoglobin A1C — the principal glycemic outcome measure (3-month average blood glucose)
• Fasting Insulin — underused but important; allows calculation of homeostatic model assessment of insulin resistance as a measure of insulin resistance
• Lipid Panel — for the berberine lipid-lowering effect (see the cholesterol deep-dive)

If a patient achieves their glycemic target on berberine, the question becomes whether to continue indefinitely or attempt periodic discontinuation. Most clinical practice favors continuing indefinitely as long as the patient is tolerating it well and the prediabetes / diabetes condition is ongoing. Berberine is best understood as a chronic management tool for a chronic condition, not a short-course intervention.

Back to Table of Contents

Key Research Papers

1. Yin J, Xing H, Ye J (2008). Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57(5):712-717. — PubMed PMID: 18442638
2. Dong H, Wang N, Zhao L, Lu F (2012). Berberine in the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Evidence-Based Complementary and Alternative Medicine 2012:591654. — PubMed PMID: 23118793
3. Lan J, Zhao Y, Dong F, et al. (2015). Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipidemia and hypertension. Journal of Ethnopharmacology 161:69-81. — PubMed PMID: 25498346
4. Zhao JV, Huang X, Zhang J, Chan YH, et al. (2023). Overall and sex-specific effect of berberine on glycemic and insulin-related traits: a systematic review and meta-analysis of randomized controlled trials. Journal of Nutrition 153(10):2939-2950. — PubMed PMID: 37598753
5. Panigrahi A, Mohanty S (2023). Efficacy and safety of berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial. BMC Endocrine Disorders 23(1):190. — PubMed PMID: 37679692 — the published title names the commercial product tested; the name is left out here.
6. Wei W, Zhao H, Wang A, Sui M, et al. (2012). A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology 166(1):99-105. — PubMed PMID: 22019891
7. Ho CE, Goh YL, Zhang C (2014). From prejudice to evidence: the case of rhizoma coptidis in Singapore. Evidence-Based Complementary and Alternative Medicine 2014:871720. — PubMed PMID: 25610485
8. Chan E (1993). Displacement of bilirubin from albumin by berberine. Biology of the Neonate 63(4):201-208. — PubMed PMID: 8513024
9. Zhang Y, Li X, Zou D, et al. (2008). Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. Journal of Clinical Endocrinology & Metabolism 93(7):2559-2565. — PubMed PMID: 18397984
10. Yang J, Yin J, Gao H, et al. (2012). Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. Evidence-Based Complementary and Alternative Medicine 2012:363845. — PubMed PMID: 22474499
11. Cheng Z, Pang T, Gu M, et al. (2006). Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochimica et Biophysica Acta. — PubMed PMID: 17049164
12. Lee YS, Kim WS, Kim KH, et al. (2006). Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55(8):2256-2264. — PubMed PMID: 16873688
13. Yin J, Ye J, Jia W (2012). Effects and mechanisms of berberine in diabetes treatment. Acta Pharmaceutica Sinica B. — PubMed
14. Zhang X, Zhao Y, Zhang M, et al. (2012). Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One. — PubMed PMID: 22880019
15. Pang B, Zhao LH, Zhou Q, et al. (2015). Application of berberine on treating type 2 diabetes mellitus. International Journal of Endocrinology. — PubMed PMID: 25861268
16. Liang Y, Xu X, Yin M, et al. (2019). Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. Endocrine Journal. — PubMed PMID: 30393248
17. Liu Y, Liao Y, Cheng C, et al. (2020). The role of berberine in preventing and treating type 2 diabetes mellitus with associated complications. Frontiers in Pharmacology. — PubMed

PubMed Topic Searches

1. PubMed: Berberine type 2 diabetes HbA1c
2. PubMed: Berberine vs metformin
3. PubMed: Berberine AMPK mechanism
4. PubMed: Berberine prediabetes
5. PubMed: Berberine insulin sensitivity
6. PubMed: Berberine GLUT4

Back to Table of Contents

Connections

• All Herbs
• Berberine Overview
• Berberine Benefits Hub
• Berberine for Cholesterol
• Berberine for Gut Health & Small Intestinal Bacterial Overgrowth
• Berberine, AMP-Activated Protein Kinase & Metabolic Syndrome
• Diabetes
• Insulin Resistance
• Metabolic Syndrome
• Polycystic Ovary Syndrome
• Hemoglobin A1C
• Fasting Insulin
• Lipid Panel
• Blood Sugar
• Gymnema
• Cinnamon
• Bitter Melon
• Inositol
• Metformin — the first-line diabetes drug berberine matched on hemoglobin A1c in the Yin 2008 head-to-head trial.
• History

Back to Table of Contents

Featured Videos

×